
Neil Fleshner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9688366/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	21.4	395
2	Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. Journal of Clinical Oncology, 2013, 31, 3069-3075.	1.6	240
3	Epidemiology and Prevention of Prostate Cancer. European Urology Oncology, 2021, 4, 877-892.	5.4	190
4	A Prostate Cancer " Nimbosus â€: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	1.9	142
5	Role of "saturation biopsy―in the detection of prostate cancer among difficult diagnostic cases. Urology, 2002, 60, 93-97.	1.0	115
6	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology, 2019, 75, 300-309.	1.9	99
7	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. European Urology, 2020, 77, 311-317.	1.9	99
8	Dietary Fat and Prostate Cancer. Journal of Urology, 2004, 171, S19-24.	0.4	83
9	Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemporary Clinical Trials, 2007, 28, 763-769.	1.8	67
10	EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS. Journal of Urology, 2005, 174, 636-641.	0.4	64
11	Prostate cancer prevention. Cancer, 2007, 110, 1889-1899.	4.1	60
12	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	1.9	57
13	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal. 2016. 10. 46.	0.6	55
14	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. Journal of Molecular Diagnostics, 2016, 18, 395-406.	2.8	46
15	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Canadian Urological Association Journal, 2014, 8, 24.	0.6	44
16	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology, 2019, 74, 474-482.	2.9	44
17	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy NaA ve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.4	44
18	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics, 2012, 7, 1037-1045.	2.7	42

#	Article	IF	CITATIONS
19	Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids. Scientific Reports, 2015, 4, 4432.	3.3	38
20	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. Radiology, 2021, 300, 369-379.	7.3	34
21	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 343-350.	1.9	33
22	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	1.6	29
23	A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clinical Epigenetics, 2018, 10, 147.	4.1	26
24	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. European Urology Oncology, 2018, 1, 238-241.	5.4	25
25	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. Journal of Urology, 2020, 204, 466-475.	0.4	24
26	Development and external validation of a biopsyâ€derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	2.5	23
27	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. Journal of Urology, 2018, 199, 1182-1187.	0.4	22
28	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. Journal of Urology, 2016, 196, 1645-1650.	0.4	19
29	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncology Letters, 2017, 14, 390-396.	1.8	19
30	Germ Cell Testicular Tumors—Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. Urology, 2019, 125, 8-19.	1.0	19
31	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgenâ€receptor–targeted therapy for metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 2587-2594.	4.1	16
32	Metabolic heterogeneity signature of primary treatment-naÃ⁻ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	1.8	16
33	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. Journal of Nuclear Medicine, 2021, 62, jnumed.120.249029.	5.0	15
34	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e17-603.e25.	1.6	14
35	Active surveillance in patients with a PSA >10 ng/mL. Canadian Urological Association Journal, 2014, 8, 702.	0.6	12
36	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. European Urology Focus, 2021, 7, 537-545.	3.1	12

#	Article	IF	CITATIONS
37	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Canadian Urological Association Journal, 2020, 14, E453-E457.	0.6	11
38	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2114694.	5.9	11
39	Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. Urology, 2019, 134, 24-31.	1.0	10
40	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. World Journal of Urology, 2020, 38, 2547-2554.	2.2	10
41	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. Journal of Urology, 2016, 195, 307-312.	0.4	9
42	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.6	9
43	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. European Urology Oncology, 2019, 2, 231-238.	5.4	9
44	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 39.e1-39.e9.	1.6	9
45	Optimizing screening and management of cardiovascular health in prostate cancer. Canadian Urological Association Journal, 2020, 14, E458-E464.	0.6	9
46	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers, 2021, 13, 3607.	3.7	9
47	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1187-1194.	0.4	9
48	A narrative review of pelvic lymph node dissection in prostate cancer. Translational Andrology and Urology, 2020, 9, 3049-3055.	1.4	9
49	Controversies in the management of testicular seminoma. Urologic Oncology, 2002, 20, 227-233.	1.5	8
50	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. Journal of Urology, 2019, 202, 1159-1165.	0.4	8
51	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Journal of Urology, 2020, 204, 416-426.	0.4	8
52	Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. Canadian Journal of Urology, 2006, 13 Suppl 3, 3-13.	0.0	8
53	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	4.5	8
54	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e13-240.e20.	1.6	7

#	Article	IF	CITATIONS
55	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	5.4	7
56	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. Journal of Urology, 2020, 204, 476-482.	0.4	7
57	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. Journal of Urology, 2014, 192, 1088-1093.	0.4	6
58	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. Canadian Urological Association Journal, 2016, 10, 424.	0.6	6
59	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality – a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2020, 23, 622-629.	3.9	6
60	Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. Canadian Urological Association Journal, 2015, 9, 14.	0.6	5
61	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. Canadian Urological Association Journal, 2019, 14, 36-41.	0.6	5
62	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients – A Cross Sectional Study. Urology, 2019, 134, 154-162.	1.0	5
63	A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?. European Urology Focus, 2021, 7, 506-507.	3.1	5
64	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. Urology, 2021, 153, 147-155.	1.0	5
65	Defining high-risk prostate cancer: current status. Canadian Journal of Urology, 2005, 12 Suppl 1, 14-7; discussion 94-6.	0.0	5
66	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. Canadian Urological Association Journal, 2021, 15, E623-E629.	0.6	4
67	The role of metformin, statins and diet in men on active surveillance for prostate cancer. World Journal of Urology, 2022, 40, 61-69.	2.2	4
68	Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn―or metachronous metastatic disease. Prostate, 2022, 82, 345-351.	2.3	4
69	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
70	Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. World Journal of Urology, 2019, 37, 799-804.	2.2	3
71	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
72	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3

#	Article	lF	CITATIONS
73	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e217-e226.	1.9	3
74	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. Cancers, 2022, 14, 1004.	3.7	3
75	Is pathology necessary to predict mortality among men with prostate-cancer?. BMC Medical Informatics and Decision Making, 2014, 14, 114.	3.0	2
76	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.4	2
77	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 431.e1-431.e8.	1.6	2
78	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis Journal of Clinical Oncology, 2020, 38, 131-131.	1.6	2
79	Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 657-658.	3.9	2
80	Prostate cancer: chemoprevention update 2005. Canadian Journal of Urology, 2005, 12 Suppl 2, 2-4.	0.0	2
81	Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. Journal of Endourology, 2022, 36, 1083-1090.	2.1	2
82	Multidimensional protein identification technology analysis highlights mitoxantroneâ€induced expression modulations in the primary prostate cancer cell proteome. Proteomics - Clinical Applications, 2009, 3, 347-358.	1.6	1
83	Is there ageism in prostate cancer detection?. Canadian Urological Association Journal, 2013, 3, 211.	0.6	1
84	Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review. Canadian Urological Association Journal, 2015, 9, 671.	0.6	1
85	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.4	1
86	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸ F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer Journal of Clinical Oncology, 2020, 38, 5553-5553.	1.6	1
87	Editorial Comment. Journal of Urology, 2019, 202, 504-505.	0.4	1
88	Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels―in Major Urology Meetings. Euro Urol 2021;80:442–9. European Urology, 2021, 81, e51-e51.	1.9	1
89	Major role for 5-alpha reductase inhibitors in the aging male. Canadian Urological Association Journal, 2007, 1, 22.	0.6	0
90	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. Canadian Urological Association Journal, 2019, 13, E292-E299.	0.6	0

#	Article	IF	CITATIONS
91	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e17-191.e24.	1.6	Ο
92	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521.	3.1	0
93	AUTHOR REPLY. Urology, 2021, 153, 155.	1.0	ο
94	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. UroOncology, 2002, 2, 93-94.	0.1	0
95	Highâ€dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5.	0.5	Ο
96	Reply by Authors. Journal of Urology, 2019, 202, 1165-1165.	0.4	0
97	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.4	ο
98	Reply by Authors. Journal of Urology, 2020, 204, 1194-1194.	0.4	0
99	Reply by Authors. Journal of Urology, 2020, 204, 475-475.	0.4	Ο
100	The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Canadian Urological Association Journal, 2021, 16, .	0.6	0
101	Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
102	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0

7